Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Joyner

Clinical Cardiac Electrophysiology Richmond, VA Medical Doctor

NPI 1609897206 CMS profile 163955

8700 Stony Point Pkwy Ste 120, Richmond, VA 23235

Open in the dashboard

General payments

$84,515

259 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$139,241 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Charles Joyner of Richmond, VA is reported in the CMS Open Payments database as having received $84,515 across 259 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $139,241 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,022 60
2024 General $3,146 34
2023 General $6,514 37
2022 General $12,633 34
2021 General $9,630 25
2020 General $6,316 10
2019 General $41,252 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Joyner
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Charles Joyner were reported at $5,022. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Charles Joyner Clinical Cardiac Electrophysiology median Middle half National median
2019 $41,252 $2,361 $585–$8,260 $163
2020 $6,316 $993 $247–$4,351 $114
2021 $9,630 $1,185 $326–$4,739 $132
2022 $12,633 $2,073 $554–$6,789 $149
2023 $6,514 $2,568 $759–$8,159 $160
2024 $3,146 $2,557 $703–$7,403 $164
2025 $5,022 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $40,391 37 payments
  2. Boston Scientific Corporation $31,654 97 payments
  3. Medtronic USA, Inc. $7,350 9 payments
  4. Abbott Laboratories $1,364 22 payments
  5. Medtronic, Inc. $578 6 payments
  6. Cardiva Medical, Inc. $547 15 payments
  7. Biosense Webster, Inc. $417 5 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $344 11 payments
  9. Impulse Dynamics (USA) Inc. $260 3 payments
  10. Merit Medical Systems Inc $250 1 payment
  11. Other $1,361 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $38,845 18 payments
  2. Consulting Fee $25,875 13 payments
  3. Food and Beverage $11,297 196 payments
  4. Travel and Lodging $8,485 31 payments
  5. Entertainment $12 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $40,391 37 payments
  2. General Therapies Therapies $10,756 15 payments
  3. General - Therapies General - Therapies_CRM $6,206 16 payments
  4. PlasmaBlade $3,927 4 payments
  5. GENERAL THERAPIES Pain Management $2,119 2 payments
  6. General - Therapies Therapies $2,100 1 payment
  7. General - Therapies General - Therapies_Non Divisional $543 5 payments
  8. WATCHMAN Access System $513 7 payments
  9. General - Therapies General - Therapies_EP $500 1 payment
  10. WATCHMAN $485 4 payments
  11. Other $7,239 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,634

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$740,177

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

35.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 436 $441,313
Xarelto Rivaroxaban Brand 250 $230,915
Entresto Sacubitril/Valsartan Brand 19 $23,068
Flecainide Acetate Generic 237 $9,102
Amiodarone Hcl Generic 226 $7,716
Dofetilide Generic 26 $5,743
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 19 $5,122
Metoprolol Succinate Generic 413 $4,581
Mexiletine Hcl Generic 29 $1,837
Sotalol Sotalol Hcl Brand 103 $1,715

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$472,285

Medicare's payments for the services billed

Medicare patients

1,089

Average age 78

Services billed

9,793

480 women, 609 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 68%
Ischemic heart disease 56%
Heart failure 49%
Arthritis 45%
Diabetes 41%
Chronic kidney disease 36%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $30
$30 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $16
$16 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $12
$12 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record